Spectrum Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SPPI research report →
About the company
Spectrum Pharmaceuticals, Inc. operates as a biopharmaceutical firm, primarily engaged in the research, development, and market introduction of innovative drug products for cancer and blood disorders. Its robust pipeline features Eflapegrastim, an advanced, long-acting granulocyte colony-stimulating factor designed to address chemotherapy-induced neutropenia.
- CEO
- Thomas J. Riga
- IPO
- 1996
- Employees
- 86
- HQ
- Boston, MA, US
Price Chart
- Market Cap
- $210.38M
- P/E
- -2.38
- P/S
- 20.80
- P/B
- 6.73
- EV/EBITDA
- -2.60
- Div Yield
- 0.00%
- Gross Margin
- 82.28%
- Op Margin
- -718.78%
- Net Margin
- -772.24%
- ROE
- -207.06%
- ROIC
- -118.37%
- Revenue
- $10.11M · 0.00%
- Net Income
- $-78,104,000 · 50.70%
- EPS
- $-0.43 · 57.84%
- Op Income
- $-72,697,000
- FCF YoY
- 18.75%
- 52W High
- $1.57
- 52W Low
- $0.32
- 50D MA
- $1.04
- 200D MA
- $0.75
- Beta
- 2.14
- Avg Volume
- 1.64M
Get TickerSpark's AI analysis on SPPI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 31, 23 | Bradrick Brittany | sell | 27,380 |
| Jul 31, 23 | Bradrick Brittany | sell | 86,301 |
| Jul 31, 23 | McGahan Keith M | sell | 778,000 |
| Jul 31, 23 | McGahan Keith M | sell | 904,077 |
| Jul 31, 23 | McGahan Keith M | sell | 195,485 |
| Jul 31, 23 | McGahan Keith M | sell | 386,057 |
| Jul 31, 23 | Lim Juhyun | sell | 75,000 |
| Jul 31, 23 | Lim Juhyun | sell | 29,759 |
| Jul 31, 23 | Lim Juhyun | sell | 22,601 |
| Jul 31, 23 | Ashton William | sell | 75,000 |
Our SPPI coverage
Recent articles, reports, and earnings notes.
No research on SPPI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SPPI report →Similar companies
Peers in the same neighborhood.